1092P Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma: 3-year subgroup analyses from RELATIVITY-047
| Autor: | Schadendorf, D., Tawbi, H.A., Hodi, F.S., Lipson, E.J., Ascierto, P.A., Medina Soto, F.A., Maio, M., Hernberg, M., Mackiewicz, J., Prey, S., Mujika Eizmendi, M.K., Atkinson, V.G., Hassel, J.C., Cinat, G., Keidel, S., Rodriguez, S., Wang, P.T., Dolfi, S., Long, G.V. |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S723-S724 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|